What does this research mean for the field?

Among intensively treated acute myeloid leukaemia patients, those with double-mutant CEBPA bZIP-inf mutations exhibit unique co-mutation profiles and superior survival outcomes compared to those with single-mutant CEBPA bZIP-inf or other CEBPA mutations. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the clinical outcomes and prognostic implications of double-mutant versus single-mutant CEBPA in-frame bZIP mutations in acute myeloid leukaemia.

August 24, 2026British Journal of HaematologyOpen Access

Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study

View Full Paper

Ask AI

Bookmark

Authors

GCGuanghui ChangPeking University PSPengcheng ShiMinistry of Education of the People's Republic of China LDLiping DouZhejiang Chinese Medical University

Discussion

Member takes

Implication

Multicentre cohort study demonstrates superior survival in acute myeloid leukaemia patients with double-mutant CEBPA bZIP in-frame mutations, indicating refined risk stratification for intensive...

Key Points

To assess the clinical outcomes and prognostic implications of double-mutant versus single-mutant CEBPA in-frame bZIP mutations in acute myeloid leukaemia.
Analyzed 411 CEBPA-mutated acute myeloid leukaemia patients across six Chinese centres.
Classified patients into four subgroups: sm CEBPA bZIP-other (n=38), sm CEBPA bZIP-inf (n=39), dm CEBPA other (n=37), and dm CEBPA bZIP-inf (n=297).
Assessed complete remission, 3-year overall survival, and disease-free survival using multivariable Cox regression models.
Patients with dm CEBPA bZIP-inf achieved higher composite complete remission (94.6% vs. 84.2%–89.2%, p = 0.025), 3-year overall survival (80.0% vs. 57.4%–70.6%, p < 0.001), and 3-year disease-free survival (74.5% vs. 45.4%–67.9%, p = 0.002).
Among intensively treated patients, dm CEBPA bZIP-inf showed superior overall survival (HR = 1.542, p = 0.017) and disease-free survival (HR = 1.618, p = 0.014) compared with sm CEBPA bZIP-inf.
In dm CEBPA bZIP-inf patients, intensive chemotherapy (HR = 0.51, p = 0.012), adverse karyotype (HR = 1.52, p = 0.037), age ≥50 years (HR = 1.74, p = 0.044), NRAS (HR = 1.64, p = 0.014), and CSF3R mutations (HR = 1.78, p = 0.049) were independent prognostic factors for overall survival.

Cite This Study

Chang et al. (2026) studied this question.

synapsesocial.com/papers/6a8c00d0bca056c88e6dfbc2 https://doi.org/10.1111/bjh.70786

View Full Paper

Ask AI

Bookmark

August 24, 2026British Journal of HaematologyOpen Access

Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study

View Full Paper

Ask AI

Bookmark

Authors

GCGuanghui ChangPeking University PSPengcheng ShiMinistry of Education of the People's Republic of China LDLiping DouZhejiang Chinese Medical University

Discussion

Member takes

Implication

Multicentre cohort study demonstrates superior survival in acute myeloid leukaemia patients with double-mutant CEBPA bZIP in-frame mutations, indicating refined risk stratification for intensive...

Key Points

To assess the clinical outcomes and prognostic implications of double-mutant versus single-mutant CEBPA in-frame bZIP mutations in acute myeloid leukaemia.
Analyzed 411 CEBPA-mutated acute myeloid leukaemia patients across six Chinese centres.
Classified patients into four subgroups: sm CEBPA bZIP-other (n=38), sm CEBPA bZIP-inf (n=39), dm CEBPA other (n=37), and dm CEBPA bZIP-inf (n=297).
Assessed complete remission, 3-year overall survival, and disease-free survival using multivariable Cox regression models.
Patients with dm CEBPA bZIP-inf achieved higher composite complete remission (94.6% vs. 84.2%–89.2%, p = 0.025), 3-year overall survival (80.0% vs. 57.4%–70.6%, p < 0.001), and 3-year disease-free survival (74.5% vs. 45.4%–67.9%, p = 0.002).
Among intensively treated patients, dm CEBPA bZIP-inf showed superior overall survival (HR = 1.542, p = 0.017) and disease-free survival (HR = 1.618, p = 0.014) compared with sm CEBPA bZIP-inf.
In dm CEBPA bZIP-inf patients, intensive chemotherapy (HR = 0.51, p = 0.012), adverse karyotype (HR = 1.52, p = 0.037), age ≥50 years (HR = 1.74, p = 0.044), NRAS (HR = 1.64, p = 0.014), and CSF3R mutations (HR = 1.78, p = 0.049) were independent prognostic factors for overall survival.

Cite This Study

Chang et al. (2026) studied this question.

synapsesocial.com/papers/6a8c00d0bca056c88e6dfbc2 https://doi.org/10.1111/bjh.70786

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark